Sentinel node biopsy in melanoma: Current controversies addressed

Area of Science:

• Oncology
• Surgical Pathology
• Dermatology

Background:

• Sentinel lymph node biopsy (SNB) is the gold standard for staging melanoma, particularly for T2/T3 tumors.
• SNB offers value in thin melanomas with adverse factors and thick melanomas (T4), despite high progression risk.
• Completion lymph node dissection (CLND) following a positive SNB identifies non-sentinel lymph node (NSN) involvement in 20% of cases.

Purpose of the Study:

• To review the role and accuracy of SNB in melanoma staging.
• To evaluate predictive factors for NSN positivity and their use in risk stratification.
• To discuss the current evidence and ongoing trials regarding CLND after positive SNB.

Main Methods:

• Review of current literature on SNB and CLND in melanoma management.
• Analysis of factors predicting NSN positivity, including tumor burden parameters.
• Discussion of clinical trial outcomes and future directions in melanoma staging.

Main Results:

• SNB is the most accurate staging tool for melanoma, indicated for various tumor thicknesses.
• Primary tumor characteristics and SN tumor burden (e.g., metastasis diameter) predict NSN positivity.
• No undisputed overall treatment benefit from SNB-based management, though subgroups may benefit. Ongoing trials (MSLT-2, EORTC 1208) will clarify CLND's role.

Conclusions:

• SNB is essential for accurate melanoma staging and risk stratification.
• Tumor burden parameters in SNB can guide decisions on adjuvant treatment or observation.
• Further research and trial results are needed to definitively establish the survival benefit of CLND after positive SNB.